- Recommendation ID
- DG16/3
- Question
- NICE recommends further research to establish optimal target dose ranges for 5-FU plasma levels in people with head and neck cancer, stomach cancer and pancreatic cancer.
- Any explanatory notes
(if applicable) - Future studies should aim to both establish the optimal target dose range for each cancer and quantify its impact on clinical outcomes, taking into account any variation that may occur between different continuous infusion 5-FU regimens.
Source guidance details
- Comes from guidance
- Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment
- Number
- DG16
- Date issued
- December 2014
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 07/01/2015 |